Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Large Real-World study tracks olaparib side effects in chinese patients

NCT ID NCT04560452

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This study observed over 1,000 Chinese patients with ovarian or prostate cancer who were already taking or starting the drug olaparib. Researchers tracked side effects and how doctors managed them in everyday practice. The goal was to better understand the drug's safety in this specific population.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,018 people

The number who actually took part.

Started

Mar 2021

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will recruit about 1000Chinese cancer patients from around 56 sites in real world practice in approved tumor types.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific procedures * Patients diagnosed as olaparib approved tumor types in China * Eligible for olaparib treatment per the judgement of the treating physician in clinical practice * For OC cohort: at least take one tablet of olaparib before enrolment * For PC cohort: according to the doctor's decision, have prescribed and agreed to start taking at least one dose of Olaparib Exclusion Criteria • In other ongoing studies, which prohibit any participation in this non-interventional study judged by investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ovarian cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ovarian cancer prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer Prostate cancer

Contacts and locations

Locations

  • Research Site

    Anhui, China

  • Research Site

    Beijing, China

  • Research Site

    Changsha, China

  • Research Site

    Chengdu, China

  • Research Site

    Chongqing, China

  • Research Site

    Dongguan, China

  • Research Site

    Foshan, China

  • Research Site

    Fujian, China

  • Research Site

    Guangdong, China

  • Research Site

    Guangzhou, China

  • Research Site

    Guangzho, China

  • Research Site

    Guizhou, China

  • Research Site

    Hangzhou, China

  • Research Site

    He'nan, China

  • Research Site

    Hebei, China

  • Research Site

    Heilongjiang, China

  • Research Site

    Henan, China

  • Research Site

    Huizhou, China

  • Research Site

    Jiangsu, China

  • Research Site

    Jiangxi, China

  • Research Site

    Jilin City, China

  • Research Site

    Jinghou, China

  • Research Site

    Liaoning, China

  • Research Site

    Luzhou, China

  • Research Site

    Nanjing, China

  • Research Site

    Nantong, China

  • Research Site

    Ningbo, China

  • Research Site

    Shandong, China

  • Research Site

    Shanghai, China

  • Research Site

    Shenyang, China

  • Research Site

    Sichuan, China

  • Research Site

    Taiyuan, China

  • Research Site

    Tianjin, China

  • Research Site

    Yichang, China

  • Research Site

    Yunan, China

  • Research Site

    Zhejiang, China

  • Research Site

    Zhengzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.